Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MLYS Mineralys Therapeutics	$14.32 -4.0%	$14.74	$8.24 ▼ $18.38	$933.31M	-0.17	510,238 shs	589,118 shs
RCUS Arcus Biosciences	$9.25 -1.1%	$8.64	$6.50 ▼ $18.98	$979.44M	0.83	879,024 shs	781,402 shs
SYRE Spyre Therapeutics	$17.29 -2.4%	$14.68	$10.91 ▼ $40.26	$1.04B	2.72	616,250 shs	325,351 shs
TVRD Cara Therapeutics	$24.62 -5.7%	$0.00	$8.13 ▼ $34.31	$230.47M	0.25	24,057 shs	51,792 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MLYS Mineralys Therapeutics	0.00%	-11.17%	-6.77%	+0.49%	+13.65%
RCUS Arcus Biosciences	0.00%	-7.45%	+7.93%	-1.02%	-41.38%
SYRE Spyre Therapeutics	0.00%	+1.89%	+18.91%	-4.16%	-53.27%
TVRD Cara Therapeutics	0.00%	-13.61%	+2,461,999,900.00%	+2,461,999,900.00%	+2,461,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MLYS Mineralys Therapeutics	2.7052 of 5 stars	3.4	3.0	0.0	0.0	1.9	4.2	0.0
RCUS Arcus Biosciences	2.2647 of 5 stars	4.5	0.0	0.0	0.0	2.6	1.7	0.0
SYRE Spyre Therapeutics	2.3978 of 5 stars	3.6	1.0	0.0	0.0	2.5	2.5	0.6
TVRD Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	125.21% Upside
RCUS Arcus Biosciences	2.90	Moderate Buy	$24.13	160.81% Upside
SYRE Spyre Therapeutics	3.25	Buy	$53.40	208.85% Upside
TVRD Cara Therapeutics	3.00	Buy	$71.50	190.41% Upside

Current Analyst Ratings Breakdown

Latest TVRD, RCUS, MLYS, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	TVRD Cara Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
5/21/2025	TVRD Cara Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
5/5/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
RCUS Arcus Biosciences	$141M	6.95	N/A	N/A	$6.17 per share	1.50
SYRE Spyre Therapeutics	$890K	1,170.98	N/A	N/A	($0.22) per share	-78.59
TVRD Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-67.97%	-62.40%	8/12/2025 (Estimated)
RCUS Arcus Biosciences	-$307M	-$4.19	N/A	N/A	N/A	-102.66%	-45.59%	-22.38%	8/4/2025 (Estimated)
SYRE Spyre Therapeutics	-$338.79M	-$3.77	N/A	N/A	N/A	N/A	-210.01%	-44.40%	8/6/2025 (Estimated)
TVRD Cara Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest TVRD, RCUS, MLYS, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.76	-$0.74	+$0.02	-$0.74	N/A	N/A
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
TVRD Cara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MLYS Mineralys Therapeutics	N/A	14.02	14.02
RCUS Arcus Biosciences	0.08	5.24	5.24
SYRE Spyre Therapeutics	N/A	7.32	7.32
TVRD Cara Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MLYS Mineralys Therapeutics	84.46%
RCUS Arcus Biosciences	92.89%
SYRE Spyre Therapeutics	80.39%
TVRD Cara Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
MLYS Mineralys Therapeutics	25.56%
RCUS Arcus Biosciences	9.60%
SYRE Spyre Therapeutics	15.43%
TVRD Cara Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	33.27 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	80.26 million	Optionable
SYRE Spyre Therapeutics	73	60.28 million	48.24 million	Optionable
TVRD Cara Therapeutics	80	9.36 million	N/A	N/A

TVRD, RCUS, MLYS, and SYRE Headlines

Recent News About These Companies

Piper Sandler Begins Coverage on Cara Therapeutics (NASDAQ:TVRD)

June 14 at 1:33 AM | americanbankingnews.com

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating

June 13 at 11:44 PM | uk.investing.com

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

June 12 at 3:07 PM | benzinga.com

Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler

June 12 at 8:22 AM | marketbeat.com

Tvardi Therapeutics Inc (TVRD)

June 7, 2025 | investing.com

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025 | businesswire.com

Cara Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Oppenheimer

May 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD, RCUS, MLYS, and SYRE Company Descriptions

Mineralys Therapeutics NASDAQ:MLYS

$14.32 -0.60 (-4.02%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$14.56 +0.23 (+1.64%)

As of 06/13/2025 04:20 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Arcus Biosciences NYSE:RCUS

$9.25 -0.10 (-1.07%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$9.24 -0.01 (-0.05%)

As of 06/13/2025 06:55 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Spyre Therapeutics NASDAQ:SYRE

$17.29 -0.42 (-2.37%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$17.28 0.00 (-0.03%)

As of 06/13/2025 05:50 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Cara Therapeutics NASDAQ:TVRD

$24.62 -1.49 (-5.71%)

As of 06/13/2025 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time